Uniphar PLC has acquired BModesto Vastgoed B.V.
Irish-listed healthcare group Uniphar PLC has acquired Dutch pharmaceutical services business BModesto Group. The acquisition strengthens Uniphar’s product access offering in Europe.
Uniphar is a global partner to pharmaceutical and medtech manufacturers working to improve patient access to medicines in Europe and around the world. It provides outsourced and specialized services to its clients and leverages strong relationships with over 200 of the world’s best-known pharmaco-medical manufacturers in multiple geographies. Uniphar operates across three core divisions: pharmaceuticals—a global business providing on-demand and medicine-sourcing solutions along with outsourced specialist services to pharmaceutical manufacturers; medtech—a leading European medical device distributor with a presence in 21 markets; and supply chain and retail—a market leader in Ireland with around 50% of the wholesale market and four nationwide pharmacy symbol groups. Uniphar is listed on the LSE and Euronext Dublin.
BModesto is a healthcare services business focused on improving access to pharmaceutical and healthcare products across the Netherlands, Germany, the UK and Europe. The company services include the distribution of medicines on both an exclusive and on-demand basis. It has a workforce of more than 180 people, and since its foundation in 2014, it has built up a strong international sourcing network to gain access to these much needed and often difficult-to-source medicines.
Oaklins’ team in Ireland acted as the exclusive buy-side M&A advisor to Uniphar and assisted in all aspects, from initiating the transaction to structuring and negotiating premium deal terms. This deal complements a long list of acquisitions the team has advised on for Uniphar.
Talk to the deal team
Related deals
Vivo Diagnóstico has been acquired by NEXXUS-IBERIA SGEIC, S.A.
NEXXUS-IBERIA SGEIC, S.A. a private equity firm in Spain, has completed its acquisition of a majority stake in Vivo Diagnóstico. With this financial backing from NEXXUS-IBERIA, Vivo will focus on inorganic growth as well as investing in service quality, innovation and efficiency.
Learn moreCreo Medical Group plc has completed a US$15.7 million equity fundraise
Creo Medical Group plc, the provider of pioneering endoscopic healthcare solutions to clinicians and healthcare providers across the world, has completed a US$15.7 million (£12.1 million) equity fundraise.
Learn morePanTera secures US$104.1 million in oversubscribed Series A round to accelerate global actinium-225 production
PanTera, a Belgian radioisotope producer, has completed a US$104.1 million (€93 million) oversubscribed Series A fundraising round led by EQT Life Sciences. Additional equity and debt funding brings the total amount raised to US$150 million (€134 million). In addition to EQT Life Sciences, the Series A round was also joined by Kurma Partners, Eurazeo, Korys, Paladin and PMV.
Learn more